134
Views
52
CrossRef citations to date
0
Altmetric
Review

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

&
Pages 1689-1704 | Published online: 23 Sep 2014

References

  • JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
  • RappEPaterJLWillanAChemotherapy can prolong survival in patients with advanced non-small-cell lung cancer – report of a Canadian multicenter randomized trialJ Clin Oncol1988646336412833577
  • SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
  • WeinsteinIBJoeAKMechanisms of disease: Oncogene addiction – a rationale for molecular targeting in cancer therapyNat Clin Pract Oncol20063844845716894390
  • GoffinJRZbukKEpidermal growth factor receptor: pathway, therapies, and pipelineClin Ther20133591282130324054705
  • McDermottUSettlemanJPersonalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncologyJ Clin Oncol200927335650565919858389
  • ShepherdFARodrigues PereiraJCiuleanuTNational Cancer Institute of Canada Clinical Trials GroupErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
  • RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
  • MokTSWuYLThongprasertSGefitinib or carboplatin- paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
  • HanJYParkKKimSWFirst-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol201230101122112822370314
  • ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
  • GainorJFShawATEmerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancerJ Clin Oncol201331313987399624101047
  • MarteBTumour heterogeneityNature2013501746732724048064
  • BurrellRAMcGranahanNBartekJSwantonCThe causes and consequences of genetic heterogeneity in cancer evolutionNature2013501746733834524048066
  • GovindanRDingLGriffithMGenomic landscape of non-small cell lung cancer in smokers and never-smokersCell201215061121113422980976
  • MeachamCEMorrisonSJTumour heterogeneity and cancer cell plasticityNature2013501746732833724048065
  • ReyaTMorrisonSJClarkeMFWeissmanILStem cells, cancer, and cancer stem cellsNature2001414685910511111689955
  • ShackletonMQuintanaEFearonERMorrisonSJHeterogeneity in cancer: cancer stem cells versus clonal evolutionCell2009138582282919737509
  • SinghSChellappanSLung cancer stem cells: Molecular features and therapeutic targetsMol Aspects Med2013 http://dx.doi.org/10.1016/j.mam.2013.08.003
  • PeacockCDWatkinsDNCancer stem cells and the ontogeny of lung cancerJ Clin Oncol200826172883288918539968
  • CarneyDNGazdarAFBunnPAJrGuccionJGDemonstration of the stem cell nature of clonogenic tumor cells from lung cancer patientsStem Cells1982131491646294885
  • RawlinsELHoganBLEpithelial stem cells of the lung: privileged few or opportunities for many?Development2006133132455246516735479
  • KimCFJacksonELWoolfendenAEIdentification of bronchioalveolar stem cells in normal lung and lung cancerCell2005121682383515960971
  • GiangrecoAArwertENRosewellIRSnyderJWattFMStrippBRStem cells are dispensable for lung homeostasis but restore airways after injuryProc Natl Acad Sci USA2009106239286929119478060
  • LinCSongHHuangCAlveolar type II cells possess the capability of initiating lung tumor developmentPLoS ONE2012712e5381723285300
  • ShienKToyookaSYamamotoHAcquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cellsCancer Res201373103051306123542356
  • Corominas-FajaBOliveras-FerrarosCCuyàsEStem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibininCell Cycle201312213390340424047698
  • HoeijmakersJHGenome maintenance mechanisms for preventing cancerNature2001411683536637411357144
  • BirkbakNJEklundACLiQParadoxical relationship between chromosomal instability and survival outcome in cancerCancer Res201171103447345221270108
  • LeeAJEndesfelderDRowanAJChromosomal instability confers intrinsic multidrug resistanceCancer Res20117151858187021363922
  • SotilloRSchvartzmanJMSocciNDBenezraRMad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawalNature2010464728743644020173739
  • AlexandrovLBNik-ZainalSWedgeDCAustralian Pancreatic Cancer Genome InitiativeICGC Breast Cancer Consortium; ICGC MMML-Seq ConsortiumICGC PedBrainSignatures of mutational processes in human cancerNature2013500746341542123945592
  • KimSCJungYParkJA high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokersPLoS ONE201382e5559623405175
  • SteadLFEganPDeveryAAn integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencingPLoS ONE2013811e7882324244370
  • BalgkouranidouILiloglouTLianidouESLung cancer epigenetics: emerging biomarkersBiomarkers Med2013714958
  • LiuSVFabbriMGitlitzBJLaird-OffringaIAEpigenetic therapy in lung cancerFront Oncol2013313523755372
  • RothschildSIEpigenetic Therapy in Lung Cancer – Role of microRNAsFront Oncol2013315823802096
  • LundAHvan LohuizenMEpigenetics and cancerGenes Dev200418192315233515466484
  • DaskalosANikolaidisGXinarianosGHypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancerInt J Cancer20091241818718823011
  • DaskalosALogothetiSMarkopoulouSGlobal DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancerCancer Lett20113001798620926182
  • HansenKDTimpWBravoHCIncreased methylation variation in epigenetic domains across cancer typesNat Genet201143876877521706001
  • BarlésiFGiacconeGGallegos-RuizMIGlobal histone modifications predict prognosis of resected non small-cell lung cancerJ Clin Oncol200725284358436417906200
  • SongJSKimYSKimDKParkSIJangSJGlobal histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patientsPathol Int201262318219022360506
  • JunttilaMRde SauvageFJInfluence of tumour micro-environment heterogeneity on therapeutic responseNature2013501746734635424048067
  • TrédanOGalmariniCMPatelKTannockIFDrug resistance and the solid tumor microenvironmentJ Natl Cancer Inst200799191441145417895480
  • MeadsMBGatenbyRADaltonWSEnvironment-mediated drug resistance: a major contributor to minimal residual diseaseNat Rev Cancer20099966567419693095
  • NakamuraTMatsumotoKKiritoshiATanoYNakamuraTInduction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactionsCancer Res19975715330533139242465
  • YamadaTMatsumotoKWangWHepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancerClin Cancer Res201016117418320008840
  • YamadaTTakeuchiSKitaKHepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancerJ Thorac Oncol20127227228022089117
  • SiegfriedJMWeissfeldLASingh-KawPWeyantRJTestaJRLandreneauRJAssociation of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancerCancer Res19975734334399012470
  • MeertAPPaesmansMMartinBThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysisBr J Cancer200287769470112232748
  • HegdePSJubbAMChenDPredictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumabClin Cancer Res201319492993723169435
  • Van der VeldtAALubberinkMBahceIRapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugsCancer Cell2012211829122264790
  • PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
  • PaoWGirardNNew driver mutations in non-small-cell lung cancerLancet Oncol201112217518021277552
  • StellaGMLuisettiMPozziEComoglioPMOncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamicsThe lancet. Respir Med201313251261
  • YuHAArcilaMERekhtmanNAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
  • JännePAEngelmanJAJohnsonBEEpidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biologyJ Clin Oncol200523143227323415886310
  • MarchettiAMartellaCFelicioniLEGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatmentJ Clin Oncol200523485786515681531
  • KosakaTYatabeYEndohHKuwanoHTakahashiTMitsudomiTMutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implicationsCancer Res200464248919892315604253
  • GarassinoMCMartelliOBrogginiMTAILOR trialistsErlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialLancet Oncol2013141098198823883922
  • BroseMSVolpePFeldmanMBRAF and RAS mutations in human lung cancer and melanomaCancer Res200262236997700012460918
  • EberhardDAJohnsonBEAmlerLCMutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibJ Clin Oncol200523255900590916043828
  • PratilasCAHanrahanAJHalilovicEGenetic predictors of MEK dependence in non-small cell lung cancerCancer Res200868229375938319010912
  • SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
  • ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
  • ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
  • JankuFStewartDJKurzrockRTargeted therapy in non-small-cell lung cancer – is it becoming a reality?Nat Rev Clin Oncol20107740141420551945
  • LorussoVSilvestrisNMarechITORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?J Clin Oncol201331228828923233717
  • LiTKungHJMackPCGandaraDRGenotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapiesJ Clin Oncol20133181039104923401433
  • MogiAKuwanoHTP53 mutations in nonsmall cell lung cancerJ Biomed Biotechnol2011201158392921331359
  • PanYZhangYLiYALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic featuresLung Cancer201484212112624629636
  • SequistLVHeistRSShawATImplementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnn Oncol201122122616262422071650
  • MitsudomiTYatabeYEpidermal growth factor receptor in relation to tumor development: EGFR gene and cancerFEBS J2010277230130819922469
  • YehPChenHAndrewsJNaserRPaoWHornLDNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapyClin Cancer Res20131971894190123344264
  • SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
  • WuJYYuCJChangYCYangCHShihJYYangPCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
  • MulloyRFerrandAKimYEpidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinibCancer Res20076752325233017332364
  • CareyKDGartonAJRomeroMSKinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinibCancer Res200666168163817116912195
  • YasudaHKobayashiSCostaDBEGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implicationsLancet Oncol2012131e23e3121764376
  • WuJYWuSGYangCHLung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment responseClin Cancer Res200814154877488218676761
  • GreulichHChenTHFengWOncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsPLoS Med2005211e31316187797
  • RielyGJPaoWPhamDClinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibClin Cancer Res2006123 Pt 183984416467097
  • DengJShimamuraTPereraSProapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrionCancer Res20076724118671187518089817
  • GongYSomwarRPolitiKInduction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomasPLoS Med2007410e29417927446
  • CraggMSKurodaJPuthalakathHHuangDCStrasserAGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsPLoS Med20074101681168917973573
  • FaberACCorcoranRBEbiHBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitorsCancer Discov20111435236522145099
  • NgKPHillmerAMChuahCTA common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNat Med201218452152822426421
  • FaberACLiDSongYDifferential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProc Natl Acad Sci USA200910646195031950819850869
  • SongLCoppolaDLivingstonSCressDHauraEBMcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cellsCancer Biol Ther20054326727615753661
  • CetinZOzbilimGErdoganALuleciGKarauzumSBEvaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFRMed Oncol201027385386019763916
  • EngelmanJAMukoharaTZejnullahuKAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancerJ Clin Invest2006116102695270616906227
  • KawanoOSasakiHEndoKPIK3CA mutation status in Japanese lung cancer patientsLung Cancer200654220921516930767
  • GerlingerMRowanAJHorswellSIntratumor heterogeneity and branched evolution revealed by multiregion sequencingN Engl J Med20123661088389222397650
  • CrouchECStoneKRBlochMMcDivittRWHeterogeneity in the production of collagens and fibronectin by morphologically distinct clones of a human tumor cell line: evidence for intratumoral diversity in matrix protein biosynthesisCancer Res19874722608660922822240
  • BlackhallFHPintilieMWigleDAStability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resectionNeoplasia20046676176715720802
  • InukaiMToyookaSItoSPresence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancerCancer Res200666167854785816912157
  • SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol200826152442244918458038
  • TurkeABZejnullahuKWuYLPreexistence and clonal selection of MET amplification in EGFR mutant NSCLCCancer Cell2010171778820129249
  • BaiHWangZWangYDetection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancerPLoS ONE201382e5417023418425
  • TaniguchiKOkamiJKodamaKHigashiyamaMKatoKIntratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinibCancer Sci200899592993518325048
  • GowCHChangYLHsuYCComparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancerAnn Oncol200920469670219088172
  • KalikakiAKoutsopoulosATrypakiMComparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLCBr J Cancer200899692392919238633
  • YatabeYMatsuoKMitsudomiTHeterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinomaJ Clin Oncol201129222972297721730270
  • MatsumotoSTakahashiKIwakawaRFrequent EGFR mutations in brain metastases of lung adenocarcinomaInt J Cancer200611961491149416642476
  • NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res200565167276728216105816
  • KamilaWKMichałSPawełKEGFR activating mutations detected by different PCR techniques in Caucasian NSCLC patients with CNS metastases: short reportClin Exp Metastasis20133081063107123892415
  • JiangSXYamashitaKYamamotoMEGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistanceInt J Cancer2008123112480248618785203
  • ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res20111751169118021248300
  • TaniguchiKUchidaJNishinoKQuantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomasClin Cancer Res201117247808781521976538
  • KleinCASelection and adaptation during metastatic cancer progressionNature2013501746736537224048069
  • SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
  • ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
  • BaiHWangZChenKInfluence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancerJ Clin Oncol201230253077308322826274
  • Jair BarDURoni Borshtein, Hovav Nechushtan, Amir Onn. EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapyChin Clin Oncol20132113
  • De PasTPelosiGde BraudFModulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rareJ Clin Oncol200422244966497015611511
  • ChinTMQuinlanMPSinghAReduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatmentClin Cancer Res200814216867687618980981
  • PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
  • KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
  • YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA200810562070207518227510
  • CostaDBSchumerSTTenenDGKobayashiSDifferential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutationsJ Clin Oncol20082671182118418309959
  • BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res200612216494650117085664
  • BeanJRielyGJBalakMAcquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaClin Cancer Res200814227519752519010870
  • CostaDBHalmosBKumarABIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsPLoS Med20074101669167917973572
  • TokumoMToyookaSIchiharaSDouble mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancerLung Cancer200653111712116730855
  • JackmanDMHolmesAJLindemanNResponse and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibJ Clin Oncol200624274517452016983123
  • ClarkeJLPaoWWuNMillerVALassmanABHigh dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJ Neurooncol201099228328620146086
  • RielyGJKrisMGZhaoBProspective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusClin Cancer Res200713175150515517785570
  • KurataTTamuraKKanedaHEffect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistanceAnn Oncol200415117317414679138
  • EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience200731658271039104317463250
  • TakezawaKPirazzoliVArcilaMEHER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationCancer Discov201221092293322956644
  • BarrSThomsonSBuckEBypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitionsClin Exp Metastasis200825668569318236164
  • UramotoHIwataTOnitsukaTShimokawaHHanagiriTOyamaTEpithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinomaAnticancer Res20103072513251720682976
  • ChungJHRhoJKXuXClinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIsLung Cancer201173217618221168239
  • WalterKHolcombTJanuarioTDNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancerClin Cancer Res20121882360237322261801
  • OgawaTLiggettTEMelnikovAAMethylation of death-associated protein kinase is associated with cetuximab and erlotinib resistanceCell Cycle20121181656166322487682
  • ZhuJWangYDuanJDNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancerJ Exp Clin Cancer Res20123118023009178
  • SalazarFMolinaMASanchez-RoncoMFirst-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patientsLung Cancer2011721849120705357
  • LiHHuHWangRPrimary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patientsOnco Targets Ther20143;7513524
  • YanoSWangWLiQHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res200868229479948719010923
  • YanoSYamadaTTakeuchiSHepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohortJ Thorac Oncol20116122011201722052230
  • MazièresJPetersSLepageBLung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJ Clin Oncol201331161997200323610105
  • WangLHuHPanYPIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroupPLoS ONE201492e8829124533074
  • CheungHWDuJBoehmJSAmplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancersCancer Discov20111760862522586683
  • KimYHKweiKAGirardLGenomic and functional analysis identifies CRKL as an oncogene amplified in lung cancerOncogene201029101421143019966867
  • DanielsMGBowmanRVYangIAGovindanRFongKMAn emerging place for lung cancer genomics in 2013J Thorac Dis20135Suppl 5S491S49724163742
  • NavinNKendallJTrogeJTumour evolution inferred by single-cell sequencingNature20114727341909421399628
  • KorfBRRehmHLNew approaches to molecular diagnosisJAMA2013309141511152123571590
  • ImielinskiMBergerAHHammermanPSMapping the hallmarks of lung adenocarcinoma with massively parallel sequencingCell201215061107112022980975
  • Network CGARCancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature2012489741751952522960745
  • PotterNEErminiLPapaemmanuilESingle-cell mutational profiling and clonal phylogeny in cancerGenome Res201323122115212524056532
  • NavinNHicksJFuture medical applications of single-cell sequencing in cancerGenome Med2011353121631906
  • JakobsenJNSørensenJBIntratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancerCancer Chemother Pharmacol201269228929922130585
  • MurtazaMDawsonSJTsuiDWNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNANature2013497744710811223563269
  • AllardWJMateraJMillerMCTumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseasesClin Cancer Res200410206897690415501967
  • MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
  • NiXZhuoMSuZReproducible copy number variation patterns among single circulating tumor cells of lung cancer patientsProc Natl Acad Sci USA201311052210832108824324171
  • KimuraHKasaharaKKawaishiMDetection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancerClin Cancer Res200612133915392116818687
  • GotoKIchinoseYOheYEpidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancerJ Thorac Oncol20127111512121900837
  • LiuXLuYZhuGThe diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologiesJ Clin Pathol201366121065106923888061
  • KuangYRogersAYeapBYNoninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancerClin Cancer Res20091582630263619351754
  • BearzattoAConteDFrattiniMp16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancerClin Cancer Res20028123782378712473590
  • HsuHSChenTPHungCHCharacterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasmaCancer200711092019202617876837
  • AnQLiuYGaoYDetection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patientsCancer Lett20021881–210911412406555
  • PorterJRStainsCISegalDJGhoshISplit beta-lactamase sensor for the sequence-specific detection of DNA methylationAnal Chem200779176702670817685552
  • PonomaryovaAARykovaEYCherdyntsevaNVPotentialities of aberrantly methylated circulating DNA for diagnostics and post-treatment follow-up of lung cancer patientsLung Cancer201381339740323806794
  • ShinYLabel-free methylation specific sensor based on silicon microring resonators for detection and quantification of DNA methylation biomarkers in bladder cancerSensors Actuators B: Chem2013177404411
  • RedovaMSanaJSlabyOCirculating miRNAs as new blood-based biomarkers for solid cancersFuture Oncol20139338740223469974
  • BoeriMVerriCConteDMicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProc Natl Acad Sci USA201110893713371821300873
  • HuZChenXZhaoYSerum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancerJ Clin Oncol201028101721172620194856
  • ZhangHSuYXuFKongJYuHQianBCirculating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokersPLoS ONE2013811e8140824282590
  • LiBRenSLiXMiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerLung Cancer2013
  • VoliniaSCalinGALiuCGA microRNA expression signature of human solid tumors defines cancer gene targetsProc Natl Acad Sci USA200610372257226116461460
  • WangYZhengDTanQWangMXGuLQNanopore-based detection of circulating microRNAs in lung cancer patientsNat Nanotechnol201161066867421892163
  • TaguchiFSolomonBGregorcVMass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional studyJ Natl Cancer Inst2007991183884617551144
  • ButtsCAVeriStrat validated in patients with non-small-cell lung cancerLancet Oncol201415767167224831978
  • GregorcVNovelloSLazzariCPredictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialLancet Oncol201415771372124831979
  • AmannJMLeeJWRoderHGenetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503J Thorac Oncol20105216917820035238
  • CarboneDPDingKRoderHPrognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trialJ Thorac Oncol20127111653166023059783
  • StinchcombeTERoderJPetermanAHA retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancerJ Thorac Oncol20138444345123370367
  • LazzariCSpreaficoABachiAChanges in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitorsJ Thorac Oncol201271404821964534
  • MilanELazzariCAnandSSAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsJ Proteomics201276Spec9110122771314
  • KwakELSordellaRBellDWIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinibProc Natl Acad Sci USA2005102217665767015897464
  • JiHZhaoXYuzaYEpidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitorsProc Natl Acad Sci USA2006103207817782216672372
  • LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene200827344702471118408761
  • KatakamiNAtagiSGotoKLUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or bothJ Clin Oncol201331273335334123816963
  • MillerVAHirshVCadranelJAfatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trialLancet Oncol201213552853822452896
  • SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
  • WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
  • YangJCShihJYSuWCAfatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialLancet Oncol201213553954822452895
  • RamalingamSSBlackhallFKrzakowskiMRandomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerJ Clin Oncol201230273337334422753918
  • YangJCHirshVSchulerMSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273342335023816967
  • SequistLVBesseBLynchTJNeratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancerJ Clin Oncol201028183076308320479403
  • ZhouWErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature200946272761070107420033049
  • NanjoSYamadaTNishiharaHAbility of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitorsPLoS ONE2013812e8470024386407
  • ReckampKLGiacconeGCamidgeDRA phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibCancer201412081145115424501009
  • JännePAvon PawelJCohenRBMulticenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancerJ Clin Oncol200725253936394417761977
  • ChiapporiAAEllisPMHammJTA phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancerJ Thorac Oncol2006191010101917409987
  • XuLKikuchiEXuCCombined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and METCancer Res201272133302331122552292
  • ChenXZhouJYZhaoJChenJJMaSNZhouJYCrizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cellsAnticancer Drugs201324101039104623962905
  • NakagawaTTakeuchiSYamadaTCombined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancerMol Cancer Ther201211102149215722844075
  • GoldmanJWLauxIChaiFPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibCancer2012118235903591122605616
  • RiceJWVealJMBarabaszATargeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinibOncol Res2009185–622924220225761
  • WangXSongXZhuoWThe regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancyProc Natl Acad Sci USA200910650212882129319965370
  • ShimamuraTLowellAMEngelmanJAShapiroGIEpidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycinsCancer Res200565146401640816024644
  • UenoTTsukudaKToyookaSStrong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancerLung Cancer2012761263121996088
  • ShimamuraTLiDJiHHsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceCancer Res200868145827583818632637
  • SocinskiMAGoldmanJEl-HariryIA multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancerClin Cancer Res201319113068307723553849
  • GaronEBFinnRSHamidiHThe HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growthMol Cancer Ther201312689090023493311
  • FerraraNThe role of vascular endothelial growth factor in pathological angiogenesisBreast Cancer Res Treat19953621271378534862
  • SetoTHigashiyamaMFunaiHPrognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancerLung Cancer2006531919616697074
  • SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
  • RSO’NeillVJFehrenbacherLPhase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancerJ Clin Oncol200725304743475017909199
  • HerbstRSJohnsonDHMininbergEPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancerJ Clin Oncol200523112544255515753462
  • HerbstRSAnsariRBustinFEfficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trialLancet201137797801846185421621716
  • JohnsonBEKabbinavarFFehrenbacherLATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancerJ Clin Oncol201331313926393424101054
  • AkerleyWBoucherKRichNA phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluationLung Cancer201379330731123273522
  • SpigelDRBurrisHAIIIGrecoFARandomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerJ Clin Oncol201129182582258921576636
  • RosellRBivonaTGKarachaliouNGenetics and biomarkers in personalisation of lung cancer treatmentLancet2013382989372073123972815
  • GaspariniGLongoRThe paradigm of personalized therapy in oncologyExpert Opin Ther Targets201216Suppl 1S7S1622073968
  • MaPCPersonalized targeted therapy in advanced non-small cell lung cancerCleve Clin J Med201279Electronic Suppl 1eS56eS6022614968